Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,744.99
(
0.32%
)
News Focus
News Focus
Post# of 257266
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: DewDiligence post# 176226

Monday, 03/31/2014 3:48:42 PM

Monday, March 31, 2014 3:48:42 PM

Post# of 257266
CBST has guided TSRX acquisition will be accretive in 2015. I think approval of tedizolid in ABSSSI will definitely reduce the risk of eventual approval in pneumonia (HABP/VABP) - ph3 trials in this indication to start soon. It makes CBST a very attractive specialty pharma IMO.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today